Skip to search formSkip to main contentSkip to account menu

netupitant / palonosetron

Known as: NETUPITANT/PALONOSETRON 
National Institutes of Health

Related topics

Related topics

2 relations
netupitantpalonosetron

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
NEPA is an oral fixed-dose combination of netupitant, a new highly selective neurokinin-1 receptor antagonist, and palonosetron… 
Review
2020
Review
2020
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
Dear Editor, Chemotherapy-induced nausea and vomiting (CINV) can be associated with reduced quality of life and meaningful… 
2020
2020
BPI20-019: Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Netupitant / Palonosetron (NEPA) vs a 3-Day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy…
2018
2018
Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting
ABSTRACT Introduction: Prevention of nausea and vomiting is of paramount importance for ensuring that patients undergoing… 
2017
2017
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy
Objective To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for… 
Review
2016
Review
2016
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
As recommended by most recent antiemetic guidelines, the optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV… 
Review
2015
Review
2015
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis
Abstract This review provides background information on chemotherapy-induced nausea and vomiting (CINV) classification and… 
Review
2015
Review
2015
Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data
Neurokinin-1 (NK1) receptor antagonists (RAs) are commonly coadministered with serotonin (5-HT3) RAs (e.g. palonosetron (PALO… 
Review
2015
Review
2015
Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials
PurposeDelayed chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of moderately emetogenic… 
Review
2014
Review
2014
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)